Use of firocoxib for the treatment of equine osteoarthritis

Josh R Donnell, David D Frisbie Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA Abstract: This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E2 r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donnell JR, Frisbie DD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/89ebd5aa2a054a409e8cb3aa3c2902ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89ebd5aa2a054a409e8cb3aa3c2902ff
record_format	dspace
spelling	oai:doaj.org-article:89ebd5aa2a054a409e8cb3aa3c2902ff2021-12-02T08:41:02ZUse of firocoxib for the treatment of equine osteoarthritis2230-2034https://doaj.org/article/89ebd5aa2a054a409e8cb3aa3c2902ff2014-11-01T00:00:00Zhttp://www.dovepress.com/use-of-firocoxib-for-the-treatment-of-equine-osteoarthritis-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034 Josh R Donnell, David D Frisbie Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA Abstract: This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E2 remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E2 from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1–3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date. Keywords: horse, osteoarthritis, firocoxib, COX-2 inhibitor, NSAIDDonnell JRFrisbie DDDove Medical PressarticleVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol 2014, Iss default, Pp 159-168 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Veterinary medicine SF600-1100
spellingShingle	Veterinary medicine SF600-1100 Donnell JR Frisbie DD Use of firocoxib for the treatment of equine osteoarthritis
description	Josh R Donnell, David D Frisbie Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA Abstract: This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E2 remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E2 from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1–3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date. Keywords: horse, osteoarthritis, firocoxib, COX-2 inhibitor, NSAID
format	article
author	Donnell JR Frisbie DD
author_facet	Donnell JR Frisbie DD
author_sort	Donnell JR
title	Use of firocoxib for the treatment of equine osteoarthritis
title_short	Use of firocoxib for the treatment of equine osteoarthritis
title_full	Use of firocoxib for the treatment of equine osteoarthritis
title_fullStr	Use of firocoxib for the treatment of equine osteoarthritis
title_full_unstemmed	Use of firocoxib for the treatment of equine osteoarthritis
title_sort	use of firocoxib for the treatment of equine osteoarthritis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/89ebd5aa2a054a409e8cb3aa3c2902ff
work_keys_str_mv	AT donnelljr useoffirocoxibforthetreatmentofequineosteoarthritis AT frisbiedd useoffirocoxibforthetreatmentofequineosteoarthritis
_version_	1718398424591630336

Use of firocoxib for the treatment of equine osteoarthritis

Ejemplares similares